{"id":10445,"date":"2020-05-23T12:38:09","date_gmt":"2020-05-23T03:38:09","guid":{"rendered":"http:\/\/aihara.la.coocan.jp\/?p=10445"},"modified":"2020-05-23T23:25:32","modified_gmt":"2020-05-23T14:25:32","slug":"%e3%82%a2%e3%83%93%e3%82%ac%e3%83%b3%e3%82%92covid-19%e6%b2%bb%e7%99%82%e3%81%ab%e4%bd%bf%e7%94%a8%e3%81%99%e3%81%b9%e3%81%8d%e3%81%8b%ef%bc%9a%ef%bc%88%ef%bc%95%ef%bc%89%e3%80%8c%e5%ae%b3%e3%80%8d","status":"publish","type":"post","link":"http:\/\/aihara.la.coocan.jp\/?p=10445","title":{"rendered":"\u30a2\u30d3\u30ac\u30f3\u3092COVID-19\u6cbb\u7642\u306b\u4f7f\u7528\u3059\u3079\u304d\u304b\uff1a\uff08\uff15\uff09\u300c\u5bb3\u300d\u306b\u95a2\u3059\u308b\u89b3\u5bdf\u7814\u7a76"},"content":{"rendered":"

\n 
\n\u30a2\u30d3\u30ac\u30f3\u306e\u6dfb\u4ed8\u6587\u66f8<\/a><\/b>\u306b\u306f\u3055\u307e\u3056\u307e\u306a\u6709\u5bb3\u4e8b\u8c61\u304c\u8a18\u8f09\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u52b9\u80fd\u52b9\u679c\u304c\u4ee5\u4e0b\u3067\u3059\u3002
\n***********************************
\n\u25cf\u518d\u8208\u578b\u30a4\u30f3\u30d5\u30eb\u30a8\u30f3\u30b6\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7
\n\u25cf\u65b0\u578b\u30a4\u30f3\u30d5\u30eb\u30a8\u30f3\u30b6\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7
\n***********************************<\/p>\n

\u30a2\u30d3\u30ac\u30f3\u306e\u300c\u5bb3\u300d\u306b\u95a2\u3057\u3066\u3001\u89b3\u5bdf\u7814\u7a76\u3092\u542b\u3081\u3066\u691c\u7d22\u3057\u305f\u7d50\u679c\u304c\u4ee5\u4e0b\u3067\u3059\u3002<\/p>\n

\u25a0\u691c\u7d22\u5f0f\uff08PubMed\uff09<\/b>
\n————————————————————
\n((Favipiravir[tiab]) AND (harm*[tiab] OR safe*[tiab] OR side effect[tiab] OR adverse*[tiab] OR toxicity[tiab])) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR meta-analysis[pt] OR meta-analysis[tiab] OR systematic review[ti] OR cochrane database syst rev[ta] OR practice guideline[pt] OR clinical trial[pt] OR observational study[pt] OR Comparative Study[tiab] OR evaluation study[tiab]))<\/p>\n

\u25a0\u691c\u7d22\u7d50\u679c\uff1a<\/b>\u30d2\u30c3\u30c8\u6570 2 (ref3\u306f#1\u3088\u308a\uff09
\n————————————————————
\n1. Lee JS, et al. Anti-Ebola Therapy for Patients With Ebola Virus Disease: A Systematic Review. BMC Infect Dis . 2019 May 2;19(1):376. doi: 10.1186\/s12879-019-3980-9. <\/p>\n

2. SissoKo D, et al. Experimental Treatment With Favipiravir for Ebola Virus Disease (The JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016 Mar 1;13(3):e1001<\/a>967. <\/p>\n

3. Bai CQ, et al. Clinical and Virological characteristics of Ebola virus disease patients treated with Favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis. 2016;63(10):1288\u201394<\/a>.<\/p>\n

\u25a0\u65b9\u6cd5\u304a\u3088\u3073\u89e3\u6790\u7d50\u679c\uff1a<\/b>
\n————————————————————
\n\u30a8\u30dc\u30e9\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u306b\u304a\u3051\u308b\u30d5\u30a1\u30d3\u30d4\u30e9\u30d3\u30eb\u4f7f\u7528\u306b\u304a\u3051\u308b\u6709\u5bb3\u4e8b\u8c61\u3092\u8abf\u67fb\u3002
\n\u30a8\u30d3\u30c7\u30f3\u30b9\u306e\u30d0\u30a4\u30a2\u30b9\u306e\u30ea\u30b9\u30af\u306f\u3001ROBINS-I\u3092\u4f7f\u3063\u3066\u8a55\u4fa1\u3002<\/p>\n

\u85ac\u7269\u4f7f\u7528\u91cf\u306f\u3001COVID-19\u306e\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u8a66\u9a13\u3088\u308a\u3082\u306f\u308b\u304b\u306b\u591a\u3044\u91cf\u3067\u3059\u3002<\/p>\n

#ref-2\uff1aFavipiravir (oral) 6000 mg on day 0, then 2400 mg daily on days 1 to 9 (111)
\n#ref-3\uff1aFavipiravir T-705 (oral) 800 mg twice on day 0 and two doses of 600 mg on subsequent days, ranging from 3 to 11 days, until discharge, transfer, or death (n = 39)<\/p>\n

\u25a0\u6709\u5bb3\u4e8b\u8c61\uff1a<\/b>
\n————————————————————
\n\u25cf\u30a2\u30d3\u30ac\u30f3\u306e\u89b3\u5bdf\u7814\u7a76\uff082\u4ef6\uff09\u306b\u304a\u3044\u3066\u30011\u4ef6\u306e\u7814\u7a76\uff08ref#3\uff09\u3067\u306f\u6709\u5bb3\u4e8b\u8c61\u306e\u300c\u5831\u544a\u306a\u3057\u300d\u3067\u3001\u4ed6\u306e1\u4ef6\u306e\u7814\u7a76\uff08ref#2\uff09\u3067\u306f\u30a2\u30d3\u30ac\u30f3\u306b\u3088\u308b\u91cd\u75c7\u6709\u5bb3\u4e8b\u8c61\u306f\u306a\u304b\u3063\u305f\u3002<\/p>\n

\u25cf\u3053\u308c\u3089\u306e\u30a8\u30d3\u30c7\u30f3\u30b9\u306eRoB\uff08ROBINS-I\uff09\u306f\u201dserious”<\/b>\u3067\u3059\u3002<\/p>\n

\u25cfRevMan\u3067\u306f\u3001\uff08RoB\u3092\u63d0\u793a\u3059\u308b\u305f\u3081\uff09\u3001\uff12\u3064\u306e\u7814\u7a76\u3067\u6709\u5bb3\u4e8b\u8c61\uff1d\uff10\u3068\u3057\u3066\u5165\u529b\u3057\u307e\u3057\u305f\u3002
\n\u3044\u305a\u308c\u306b\u3057\u3066\u3082\u3001<\/p>\n

\u25cfROBINS-I\u3092\u4f7f\u3063\u305fGRADE\u8a55\u4fa1\u3067\u306f\u3001\u3053\u306e\u30a8\u30d3\u30c7\u30f3\u30b9\u306fRoB\u306b\u95a2\u3057\u3066\u3001\u201d2\u6bb5\u968e\u30b0\u30ec\u30fc\u30c9\u30c0\u30a6\u30f3\u201d\u3067\u3059\u3002<\/b><\/span><\/p>\n

\"\"<\/a><\/p>\n

\n

\u3000
\n\u25cfGRADE\u306b\u3088\u308b\u6700\u7d42\u7684\u306a\u30a8\u30d3\u30c7\u30f3\u30b9\u306e\u78ba\u5b9f\u6027\u306f\u300cLow\u300d
\n\uff08GRADE\/ROBINS-I\uff09<\/b><\/span><\/div>\n

\"\"<\/a><\/p>\n

******************************
\n\u25cf\u4ee5\u4e0a\u304b\u3089\u3001COVID-19\u3067\u4f7f\u7528\u3055\u308c\u3066\u3044\u308b\u30a2\u30d3\u30ac\u30f3\u306e\u91cf\u3084\u671f\u9593\u304b\u3089\u306f\u3001\u6709\u5bb3\u4e8b\u8c61\u306f\u5c11\u306a\u3044\u3068\u601d\u3044\u307e\u3059\u3002
\n\u25cf\u306a\u304a\u3001\uff11\uff5e\uff12\u304b\u6708\u4ee5\u5185\u306b\u306f\u3001\u5bcc\u58eb\u30d5\u30a3\u30eb\u30e0\u306e\u7b2c3\u76f8\u6cbb\u9a13\u306e\u7d50\u679c<\/b><\/a>\u304c\u308f\u304b\u308b\u3088\u3046\u3067\u3059\u3002
\n\u25cf\u307e\u305f\u3001\u6d77\u5916\u304b\u3089\u30e1\u30bf\u30a2\u30ca\u30ea\u30b7\u30b9\u3082\u767a\u8868\u3055\u308c\u308b\u3088\u3046\u3067\u3059\u3002<\/p>\n

\n <\/p>\n","protected":false},"excerpt":{"rendered":"

  \u30a2\u30d3\u30ac\u30f3\u306e\u6dfb\u4ed8\u6587\u66f8\u306b\u306f\u3055\u307e\u3056\u307e\u306a\u6709\u5bb3\u4e8b\u8c61\u304c\u8a18\u8f09\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u52b9\u80fd\u52b9\u679c\u304c\u4ee5\u4e0b\u3067\u3059\u3002 *********************************** \u25cf\u518d\u8208\u578b\u30a4\u30f3\u30d5\u30eb\u30a8\u30f3\u30b6\u30a6\u30a4\u30eb\u30b9\u611f\u67d3\u75c7 \u25cf\u65b0\u578b\u30a4\u30f3\u30d5\u30eb […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[470],"tags":[],"_links":{"self":[{"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/posts\/10445"}],"collection":[{"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10445"}],"version-history":[{"count":22,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/posts\/10445\/revisions"}],"predecessor-version":[{"id":10472,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=\/wp\/v2\/posts\/10445\/revisions\/10472"}],"wp:attachment":[{"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10445"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/aihara.la.coocan.jp\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}